Oncology Peer Review On-The-Go: Treatment Options for Relapsed/Refractory Small Cell Lung Cancer
Wade Iams, MD, broke down some of the different treatment options, including lurbinectedin and topotecan, for patients with relapsed/refractory small cell lung cancer in the second episode of a 4-part small cell lung cancer podcast series.
In the second part of our 4-part series on small cell lung cancer (SCLC), CancerNetwork® continued its conversation with Wade Iams, MD, a thoracic medical oncologist at Vanderbilt University Medical Center. Iams turned attention towards different treatment options that are currently available for patients with relapsed/refractory SCLC. Among others, Iams touched on lurbinectedin (Zepzelca), topotecan, and some of the crucial clinical trials associated with treatment options for SCLC. These studies included a phase 2 basket trial (NCT02454972) that assessed the use lurbinectedin as a second-line therapy in relapsed SCLC and phase 3 ATLANTIS trial (NCT02566993), which examined second-line lurbinectedin in combination with doxorubicin in patients with SCLC.
Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify, or anywhere podcasts are available.
Check out the first episode of this series on first-line therapeutic options in small cell lung cancer.
